VEGF与恶性胸腔积液的相关研究进展

Research Progress on VEGF and Malignant Pleural Effusion

恶性胸腔积液是通过恶性肿瘤直接或间接侵犯胸膜导致,其发生发展严重影响患者的生存质量及预后。血管内皮细胞生长因子(VEGF)可以促进新生血管的生成及增加血管的通透性,并可通过一系列信号传导通路及分子途径促进肿瘤组织的生长、转移和复发,其对恶性胸腔积液的生成发挥关键作用。目前研究发现,重组人血管内皮抑素联合化疗药物治疗恶性胸腔积液可明显提高疗效且不增加毒副反应,其通过切断血管生成的途径,延缓肿瘤发生发展,值得临床继续深入研究及推广。

Malignant pleural effusion is caused by maugnam tumors directly or indirectly caused by the pleural infiltration, the occurrence and development of patients with serious impact on the quality of life and prognosis. VEGF （vascular endothelial growth factor） can promote the formation of new blood vessels and in-crease vascular permeability, and through a series of signaling pathways and molecular pathways to promote tu-mor growth, metastasis and recurrence of malignant pleural effusion Generate play a key role. The current study found that recombinant human endostatin combined with chemotherapy drugs in the treatment of malignant pleural effusion can significantly improve the efficacy and does not increase the toxicity, which by cutting off the pathway of angiogenesis, delaying tumor development, it is worth further study and promotion of clinical.